Bromocriptine-QR, a quick release formulation of bromocriptine, a sympatholytic dopamine D2 receptor agonist [22, 23] (approved by the U.S. Food and Drug Administration for the treatment of hyperglycemia in patients with T2DM in 2009) may offer a therapy with the potential to maintain glycemic control and reduce CVD risk [24–28]. This evidence concerns the gene DRD2 and type 2 diabetes mellitus.